Finance Leadership for Early Stage MedTech

I work with Series A and Series B medtech companies on financial strategy, scenario planning, and investor preparation. I’m a former CEO and investor with quantitative expertise and published research on early-stage financing. I help you navigate fundraising, model uncertainty, and make smart financial decisions. I’ve been the restructuring CEO when things went wrong—let’s make sure that’s not your story.

Schedule a First Call

Trusted By…

I work with Series A/B medtech companies, their investors, and boards. Past and current clients include:

Who I Work With

I primarily work with Series A and Series B medtech companies—typically those with $3-20M raised, 12-24 months of runway, and facing their next fundraise or a strategic inflection point.

Most clients find me through investor or board member referrals when they need:

  • Financial strategy and scenario planning for an upcoming raise
  • Cash runway modeling that accounts for clinical and regulatory uncertainty
  • Someone who understands both sides of the table as former CEO and investor

I also work with boards and investors when portfolio companies face operational or financial crises.

What I Do

Financial Strategy & Scenario Planning

I build financial models that incorporate both upside and downside uncertainty: faster-than-expected enrollment alongside potential timeline extensions, partnership opportunities that accelerate or fall through, burn rate variations. Monte Carlo simulations show you the range of outcomes and when you might hit “fumes” or reach profitability under different scenarios.

Fundraising Preparation & Support

I prepare you for investor diligence, help structure your ask, and develop financial projections investors will believe. I provide at-the-elbow support during investor conversations and term sheet negotiations, drawing on experience from both sides of the table.

Cash & Runway Management

I analyze your runway under different scenarios and help you make decisions about spending, timing, and risk. This includes understanding when you’re truly out of options and when you have room to be aggressive.

Crisis Stabilization

When financing fails, operations break down, or board conflicts emerge, I help stabilize the situation. As a former restructuring CEO, I know how to navigate difficult conversations and make hard decisions under pressure.

What Clients Say

Experienced Start-Up Investor, Board Member, Exiting Founder

Amidst a real crisis, he was asked to step in first to right the ship and ultimately to restructure the company altogether.  If I ever again needed to find someone who can step in and manage a clinical stage MedTech in trouble he is the only person I would think of calling.

Principal, Early Stage Investment Firm

As a board observer, I have worked closely with John in his role as restructuring CEO.  He is very perceptive and readily understands nuanced issues. He is deft at managing competing interests, differing visions and building a consensus.

Research Cardiologist, International Clinical Trialist

During the pandemic, John chaired the Data and Safety Monitoring Board for two international randomized controlled trials for new COVID therapeutics on which I was the lead investigator. He was very knowledgeable and responsive, promptly available for urgent questions and always thoughtful, keeping the safety of participants in mind, while emphasizing data integrity and the practicalities of trial execution.

Senior Executive, Large Scale Commercial and Scientific Real Estate Developer

John was an invaluable consultant as we sought an edge in an increasingly competitive and efficient life science market. He provided immediate value due to his exceptional understanding of the life science start-up community in a context that’s accessible and valuable to real estate investors and developers. His data driven approach to market analysis – including supply/demand fundamentals, types of end users and their real estate needs far exceeding our prior experience.  He’s also exceptionally well-connected nationally and can help with essential introductions to life science leaders in every facet of the industry.

John Younger, MD — medtech turnaround and crisis consultant and founder of ArgoPond

About John Younger, MD

I'm a former medtech CEO, investor, and board member. I've raised capital, navigated complex financings, and led a contentious restructuring that avoided litigation. I've been on both sides of the table—as founder pitching investors and as investor evaluating deals.

My clinical background (20+ years in emergency medicine and critical care) means I understand how devices actually get used, what drives clinician adoption, and how reimbursement works. I combine that with quantitative expertise—masters in biostatistics, published research on startup financing, and congressional testimony on life science policy. I build financial models that help management teams and boards make decisions under uncertainty.

Operating experience, clinical insight, and analytical rigor—that's what helps me spot problems and opportunities others miss. I work with Series A/B companies that need strategic finance expertise—scenario modeling, fundraising strategy, board-level financial decisions.

Selected Publications & Testimony:
Current Research:
  • A Receiver's Primer on Director and Officer Insurance (In press, NAFER Receiver)
  • Long-term trends in pediatric orthopedic start-up financing (Under review)
  • Cash-flow-based revolving loan mechanisms (Work in progress)